Latest Period
Q2 2026
Security Snapshot
Dyne Therapeutics, Inc. - COMMON STOCK, $0.0001 PAR VALUE (DYN) Institutional Ownership
CUSIP: 26818M108
13F Institutional Holders and Ownership History from Q3 2020 to Q2 2026
Institutions Reporting
245
Shares (Excl. Options)
190,475,935
Price
$22.21
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK, $0.0001 PAR VALUE
- Symbol
- DYN on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 190,475,935
- Total 13F value
- $4,226,754,444
- Portfolio coverage rank
- 0.01%
- Share change
- +4,462,733
- Value change
- +$105,062,988
- Number of holders
- 245
- Shares outstanding
- 186,643,708
- SEC-reported price per share
- $25.73
- Insider filing price
- $25.73
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- DYN - Dyne Therapeutics, Inc. - COMMON STOCK, $0.0001 PAR VALUE is tracked under CUSIP 26818M108.
- 245 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 228 to 245 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $3,402,807,857 to $4,226,754,444.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 245 institutions filings for Q2 2026.
Security key
26818M108
Latest holder period
Q2 2026
13F holders
245
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
DYN full holder history
Dyne Therapeutics, Inc. SEC filings
Dyne Therapeutics, Inc. company facts
Dyne Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 26818M108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
DYN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19% | +16% | $557,222,998 | +$76,153,288 | 30,785,801 | +16% | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 |
| Janus Henderson Group Ltd. | 7.3% | -12% | $283,626,526 | -$38,997,442 | 11,997,738 | -12% | JANUS HENDERSON GROUP Ltd. | 30 Jun 2026 |
| BlackRock, Inc. | 7% | +20% | $255,181,884 | +$109,087,191 | 11,489,504 | +75% | BlackRock, Inc. | 30 Jun 2026 |
| FMR LLC | 6.8% | +28% | $264,933,477 | +$54,325,193 | 11,207,000 | +26% | FMR LLC | 30 Jun 2026 |
| Forbion Capital Fund IV Cooperatief U.A. | 4.8% | $60,000,055 | 5,400,545 | ForDyne B.V. | 31 Mar 2025 | |||
| Atlas Venture Fund XI, L.P. | 2.4% | -40% | $105,894,174 | -$29,172,256 | 4,479,449 | -22% | Atlas Venture Associates XI, L.P. | 30 Jun 2026 |
| RTW INVESTMENTS, LP | 1.5% | -72% | $18,782,199 | -$39,196,902 | 1,690,567 | -68% | RTW Investments, LP | 31 Mar 2025 |
| Point72 Asset Management, L.P. | 1.5% | -72% | $18,546,390 | -$39,187,803 | 1,669,342 | -68% | Point72 Asset Management, L.P. | 31 Mar 2025 |
As of 30 Jun 2026, 245 institutional investors reported holding 190,475,935 shares of Dyne Therapeutics, Inc. - COMMON STOCK, $0.0001 PAR VALUE (DYN). This represents 102% of the company’s total 186,643,708 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
78%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 17% | 30,912,287 | +0.41% | 0.45% | $686,562,000 |
| BlackRock, Inc. | 6.6% | 12,404,330 | +6% | 0% | $275,500,169 |
| Jupiter Topco LLC | 6.4% | 11,997,738 | 0% | 0.11% | $266,634,150 |
| FMR LLC | 6% | 11,207,000 | +26% | 0.01% | $248,907,468 |
| STATE STREET CORP | 4% | 7,458,263 | +12% | 0% | $165,648,021 |
| Orbis Allan Gray Ltd | 3.8% | 7,006,542 | +3.6% | 0.53% | $155,615,298 |
| Atlas Venture Life Science Advisors, LLC | 3.6% | 6,800,099 | -26% | 17% | $151,030,199 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 6,310,969 | -1.5% | 0% | $140,166,621 |
| TCG Crossover Management, LLC | 2.5% | 4,615,144 | 0% | 2.5% | $102,502,348 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.2% | 4,048,428 | -2.7% | 0% | $89,915,586 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.1% | 3,936,806 | +69% | 0.01% | $87,438,000 |
| FCPM III SERVICES B.V. | 2.1% | 3,848,256 | -17% | 11% | $85,469,766 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 3,743,427 | +6.8% | 0% | $83,158,757 |
| Vestal Point Capital, LP | 1.8% | 3,375,000 | -16% | 1.8% | $74,958,750 |
| ORBIMED ADVISORS LLC | 1.7% | 3,235,684 | +11% | 1.4% | $71,864,542 |
| Frazier Life Sciences Management, L.P. | 1.7% | 3,153,082 | 0% | 1.5% | $70,029,951 |
| JPMORGAN CHASE & CO | 1.7% | 3,151,656 | -3.1% | 0% | $67,154,494 |
| ARMISTICE CAPITAL, LLC | 1.7% | 3,087,226 | -2.8% | 1.9% | $68,567,289 |
| PERCEPTIVE ADVISORS LLC | 1.4% | 2,689,235 | -42% | 0.93% | $59,727,909 |
| Logos Global Management LP | 1.4% | 2,550,000 | +82% | 2.4% | $56,635,500 |
| BANK OF AMERICA CORP /DE/ | 1.2% | 2,233,398 | +55% | 0% | $49,603,770 |
| Venrock Adviser, LLC | 1.2% | 2,173,913 | 0% | 1.5% | $48,282,608 |
| GOLDMAN SACHS GROUP INC | 1.2% | 2,157,195 | +25% | 0.01% | $47,911,301 |
| Siren, L.L.C. | 1.1% | 2,129,125 | -4.5% | 0.96% | $47,287,866 |
| FRANKLIN RESOURCES INC | 1.1% | 2,030,819 | +1.1% | 0.01% | $45,104,481 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q2 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 190,475,935 | $4,226,754,444 | +$105,062,988 | $22.21 | 245 |
| 2026 Q1 | 187,866,029 | $3,402,807,857 | +$164,905,709 | $18.13 | 228 |
| 2025 Q4 | 177,889,406 | $3,479,400,136 | +$511,413,774 | $19.56 | 232 |
| 2025 Q3 | 155,774,921 | $1,970,440,035 | +$381,733,004 | $12.65 | 205 |
| 2025 Q2 | 128,553,808 | $1,223,875,095 | +$58,226,785 | $9.52 | 195 |
| 2025 Q1 | 121,788,688 | $1,284,331,056 | -$75,923,327 | $10.46 | 202 |
| 2024 Q4 | 111,635,776 | $2,630,327,572 | -$39,471,758 | $23.56 | 199 |
| 2024 Q3 | 112,428,939 | $4,033,469,001 | -$6,349 | $35.92 | 200 |
| 2024 Q2 | 110,972,098 | $3,915,861,443 | +$555,159,053 | $35.29 | 191 |
| 2024 Q1 | 95,365,001 | $2,707,385,907 | +$786,881,972 | $28.39 | 167 |
| 2023 Q4 | 69,922,072 | $929,957,219 | +$57,596,260 | $13.30 | 123 |
| 2023 Q3 | 59,888,832 | $536,594,556 | +$1,685,315 | $8.96 | 114 |
| 2023 Q2 | 59,189,838 | $665,851,766 | +$50,911,029 | $11.25 | 117 |
| 2023 Q1 | 54,627,733 | $628,721,822 | +$56,536,368 | $11.52 | 125 |
| 2022 Q4 | 49,732,095 | $576,377,450 | +$50,130,248 | $11.59 | 112 |
| 2022 Q3 | 44,533,854 | $565,571,380 | -$9,010,573 | $12.70 | 100 |
| 2022 Q2 | 46,679,856 | $320,706,640 | -$8,056,035 | $6.87 | 87 |
| 2022 Q1 | 47,256,134 | $455,432,690 | -$4,233,139 | $9.64 | 90 |
| 2021 Q4 | 47,794,946 | $568,260,037 | +$18,929,604 | $11.89 | 90 |
| 2021 Q3 | 32,306,202 | $524,727,164 | -$16,367,213 | $16.24 | 80 |
| 2021 Q2 | 35,805,078 | $753,366,735 | +$36,093,361 | $21.04 | 75 |
| 2021 Q1 | 31,379,394 | $487,292,000 | +$72,426,450 | $15.53 | 72 |
| 2020 Q4 | 26,339,155 | $552,433,805 | +$28,795,524 | $21.00 | 67 |
| 2020 Q3 | 24,527,914 | $493,744,000 | +$493,744,015 | $20.19 | 49 |